newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference

Confirmed Objective Response Rate of 48 Percent in Patients with NTRK+ TKI-Pretreated Advanced Solid Tumors Confirmed Objective Response Rate of 62 Percent in NTRK+ TKI-Pretreated Advanced Solid Tumor Patients with Solvent Front Mutations Breakthrough